Oct 30 (Reuters) -
* S&P - Valeant Pharmaceuticals International Inc (N:VRX) downgraded to 'B+' from
'BB-'; outlook negative
* S&P - given multitude of issues that Valeant faces, revising assessment of
management and governance to 'weak' from 'fair'
* S&P on Valeant - "believe that the company's ability to grow organically will
be constrained going forward"
* Source text - http://bit.ly/20gDDFI